Canada markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
147.55-0.85 (-0.57%)
At close: 4:00PM EDT

147.60 +0.05 (0.03%)
After hours: 7:51PM EDT

Full screen
Trade prices are not sourced from all markets
Previous Close148.40
Open148.40
Bid147.25 x 1200
Ask147.79 x 900
Day's Range146.50 - 149.25
52 Week Range109.16 - 157.00
Volume4,835,493
Avg. Volume6,887,310
Market Cap388.473B
Beta (5Y Monthly)0.69
PE Ratio (TTM)25.96
EPS (TTM)5.68
Earnings DateOct. 13, 2020
Forward Dividend & Yield4.04 (2.72%)
Ex-Dividend DateAug. 24, 2020
1y Target Est166.06
  • Editor's Pick
    Yahoo Finance Video

    ‘We need to make sure that the science and safety is there’ so people can trust the vaccine: doctor

    The conversation around pricing vaccinations and distribution is ramping up as more pharmaceuticals announce positive test results. Dr. Rob Davidson, a West Michigan ER doctor and the Executive Director of the Committee to Protect Medicare, joins The Final Round panel to discuss his views on the coronavirus vaccine front.

  • Baystreet

    More Highs for TSX

    Canada's main stock index scaled a five-month high on Thursday as a surge in shares of drugmaker Bausch ...

  • Reuters

    U.S. FDA approves GlaxoSmithKline's blood cancer drug

    The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's experimental treatment for a common form of blood cancer. GSK's belantamab mafodotin, or BLENREP, was approved for treating adults with relapsed and refractory multiple myeloma who no longer respond to treatment with an immunomodulatory agent, the drugmaker said in a statement. Multiple myeloma is the second most common form of blood cancer in the U.S. and is generally considered treatable, but not curable.